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Chimeric yellow fever (YF)–dengue (DEN) viruses (ChimeriVax–DEN) were reconstructed to correct amino acid substitu-
tions within the envelope genes of original constructs described by Guirakhoo et al. (2001, J. Virol. 75, 7290–7304). Viruses
were analyzed and compared to the previous constructs containing mutations in terms of their growth kinetics in Vero cells,
neurovirulence in mice, and immunogenicity in monkeys as monovalent or tetravalent formulations. All chimeras grew to high
titers [7 to 8 log10, plaque-forming units (PFU)/ml] in Vero cells and were less neurovirulent than YF 17D vaccine in mice.
For monkey experiments, the dose of DEN2 chimera was lowered to 3 log10 PFU in the tetravalent mixture in an effort to
reduce its dominant immunogenicity. The magnitude of viremia in ChimeriVax–DEN immunized monkeys was similar to that
of YF-VAX, but significantly lower than those induced by wild-type DEN viruses. All monkeys developed high levels of
neutralizing antibodies against homologous (chimeras) or heterologous (wild-type DEN viruses isolated from different
geographical regions) viruses after a single dose of monovalent or tetravalent vaccine. Administration of a second dose of
tetravalent vaccine 2 months later increased titers to both homologous and heterologous viruses. A dose adjustment for
dengue 2 chimera resulted in a more balanced response against dengue 1, 2, and 3 viruses, but a somewhat higher response
against chimeric dengue 4 virus. This indicates that further formulations for dose adjustments need to be tested in monkeys
to identify an optimal formulation for humans. © 2002 Elsevier Science (USA)INTRODUCTION
Dengue (DEN), a positive-stranded RNA virus, is a
member of the Flaviviridae family, which contains more
than 70 viruses. Dengue viruses are transmitted to hu-
mans by mosquitoes (mainly by Aedes aegypti) and are
the cause of a growing public health problem worldwide.
Fifty to 100 million persons are infected annually, and
rates of infection are as high as 6% in some areas
(Gubler, 1997; Burke et al., 1988).
Four serotypes (DEN1–4) circulate in the Caribbean,
Asia, and the Americas. The severe, potentially lethal
form of DEN infection [dengue hemorrhagic fever/den-
gue shock syndrome (DHF/DSS)] is an immunopatholog-
ical disease occurring in individuals who sustained se-
quential infections with different DEN serotypes. Over 3.6
million cases and 58,000 deaths caused by DHF were
reported between 1980 and 1995 (Halstead, 1997). Be-
cause of the pathogenesis of DHF/DSS, it is generally
accepted that a successful DEN vaccine would immu-
1 To whom correspondence and reprint requests should be ad-© 2002 Elsevier Science (USA)
All rights reserved.
146nize against all four serotypes simultaneously and in-
duce long-lasting immunity. Despite extensive efforts
since World War II, there is no approved DEN vaccine
available.
We previously reported constructions of four DEN chi-
meras (ChimeriVax–DEN1 to –DEN4). These recombi-
nant vaccines were developed using an infectious clone
of yellow fever 17D virus, into which the envelope genes
of wild-type (wt) DEN viruses were inserted (Guirakhoo
et al., 2001). These chimeras grew to high titers in Vero
cells and were immunogenic in monkeys inoculated with
monovalent or tetravalent formulations (i.e., a mixture of
equal concentrations of each monovalent chimeric vi-
rus). However, it was noticed that in monkeys immunized
with the tetravalent formulation, the highest immune re-
sponse was directed toward the ChimeriVax–DEN2 vi-
rus. In vitro growth kinetics studies also revealed that
ChimeriVax–DEN2 replicated more rapidly than the other
three chimeras. Sequences of chimeric DEN2 had re-
vealed no mutations, but the DEN1, DEN3, and DEN4
chimeras contained a few mutations in the premem-
brane and envelope (prME) regions. These mutationsKey Words: dengue virus; tetravalent vaccine; chimer
neurovirulence.
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had apparently been introduced during the construction
of these chimeras, either intentionally upon introductionic viru
of new restriction sites or unintentionally due to errors
introduced by RT-PCR amplification of the prME genes of
parental DEN viruses.
To determine whether these mutations affected the
growth rates of chimeric viruses in Vero cells or their
safety and immunogenicity profiles in vivo, we recon-
structed chimeric viruses without unnecessary muta-
tions and evaluated them for their in vitro growth kinetics,
mouse neurovirulence, viremia, and immunogenicity in
monkeys. This paper also contains the results of our first
attempt to adjust the tetravalent vaccine formulation
aimed at achieving optimal and uniform replication of all
four chimeric viruses in monkeys.
RESULTS
Reconstruction of ChimeriVax–DEN1, –DEN3, and
–DEN4 viruses
The sequences of the prME regions of reconstructed
viruses were compared to wt consensus sequences
(parent DEN wt viruses from which the prME genes were
derived) (Table 1). In contrast to the original chimeras,
which had contained some mutations within the prME
regions, all reconstructed viruses were free of uninten-
tional mutations, with the exception of one mutation in
the DEN1 chimera and one nucleotide heterogeneity in
the DEN3 chimera (see below). ChimeriVax–DEN100 and
–DEN400 viruses maintained mutations at position E494,
which had been created intentionally for insertion of a
NarI restriction site. In the case of ChimeriVax–DEN300
virus, it was possible to replace NarI with a PvuII restric-
tion site, which did not result in an amino acid substitu-
tion. The DEN3 specificity of the new chimeric virus was
first confirmed by RT-PCR–restriction digestion analysis.
The prME regions of the virus from passages 5 and 6 (P5
and P6) posttransfection were then sequenced to detect
mutations. The only mutation detected was a nucleotide
heterogeneity (A/C) at nt 535 (nt 54 from beginning of the
prM gene), which results in a conservative amino acid
(E/D) heterogeneity at position 18 of prM. Sequencing of
the corresponding plasmids revealed no mutation, indi-
cating that this heterogeneity had occurred during in
vitro virus passages. ChimeriVax–DEN100 still contained
an A to G mutation, resulting in an amino acid substitu-
tion from H to R at the M39 position. Sequencing of the
corresponding plasmids used to construct this chimera
revealed the same mutation. This mutation was cor-
TABLE 1
Amino Acid Differences (in the prME Region) between Chimeric Viruses and Their Parent Wild-type Viruses
ChimeriVax– Gene
Nucleotide
No.a
Nucleotide
change
Amino acid
change
Amino acid
No.b Comments
DEN199
c (VeroP4) M 389 A to G H to R 39 Present in plasmid
E 1109 A to G K to R 204
E 1978–1980 CAG to GGC Q to G 494 Created to insert NarI
DEN100 (VeroP2) M 389 A to G H to R 39 Present in plasmid
E 1978–1980 CAG to GGC Q to G 494 Created to insert NarI
DEN399
c (VeroP4) E 1964 C to T A to V 489
E 1972–1974 CAA to GGC Q to G 492 Created to insert NarI
DEN300 (VeroP5) PrM 54 A/C E/D 18 Likely not present in mature virions
DEN499
c (VeroP3) M 400 G to A A to T 43
E 508 G to A V to I 4
E 666 A to T L to F 56 Created to insert BstBI
E 1807 C to T H to Y 437
1978–1980 CAA to GGC Q to G 494 Created to insert NarI
DEN499 (VeroP8,
large plaque)c
M 400 G to A A to T 43
E 666 A to T L to F 56 Created to insert BstBI
E 1327 C to A H to N 277
E 1595 A to G N to S 366
E 1807 C to T H to Y 437
E 1977–1980 CAA to GGC Q to G 494 Created to insert NarI
DEN499 (VeroP8,
small plaque)c
M 400 G to A A to T 43
E 666 A to T L to F 56 Created to insert BstBI
E 1977–1980 CAA to GGC Q to G 494 Created to insert NarI
DEN400 (VeroP5) E 1978–1980 CAA to GGC Q to G 494 Created to insert NarI
a From the beginning of the prME gene.
b From the N-terminus of the proteins (M or E).
c Described in Guirakhoo et al. (2001). ChimeriVax–DEN499 viruses were a mixed population of small to large plaques in Vero cells. Plaques were
subjected to three rounds of amplifications and purifications to create two homogeneous populations, small and large sizes at passage 8 (P8)
posttransfection. The titers of small- and large-plaque virus stocks prepared at P8 in Vero cells were 6.9 and 7.1 log10 PFU/ml, respectively.
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rected later in a plasmid used to create the ChimeriVax–
DEN101 virus (K. V. Pugachev, unpublished data).
Growth characteristics
The reconstructed ChimeriVax–DEN viruses were
evaluated for their replication efficiencies in Vero cells.
Their growth kinetics were compared to those of their
predecessors, which contained mutations in the prME
regions. ChimeriVax–DEN199 and ChimeriVax–DEN100 vi-
ruses consisted of a mixed plaque (small and large)
population. These viruses were plaque purified, and
seed stocks of large (1.5–3.0 mm) and small (1.5 mm)
plaques were prepared for use in growth kinetics stud-
ies. A Research Master Seed (RMS) of ChimeriVax–
DEN2 virus (VeroP3) was used as a control for these
assays (Fig. 1A). All plaque-purified virus samples re-
vealed similar plaque size distributions (1.5–3.0 mm in
diameter), irrespective of their original small or large
plaque sizes. Both small- and large-plaque ChimeriVax–
DEN100 variants (tested at m.o.i. 0.002 and 0.006, respec-
tively) reached maximum titers on Day 4 (7.8 and 7.6 log10
PFU/ml, respectively). In contrast, ChimeriVax–DEN199
large plaque and ChimeriVax–DEN2 RMS (tested at
m.o.i. 0.004 and 0.02, respectively) reached a maximum
titer of 7.6 one day earlier (on Day 3).
The growth property of ChimeriVax–DEN300 virus was
examined following infection of Vero cells at an m.o.i. of
0.01. As shown in Fig. 1B, this virus grew to a peak titer
FIG. 1. Growth kinetics of ChimeriVax–DEN viruses in Vero cells. (A) Growth kinetics of ChimeriVax–DEN199 P3, and ChimeriVax–DEN100
large-plaque phenotypes at P4. (B) Growth kinetics of ChimeriVax–DEN300 (containing NarI or PvuII restriction sites at the E/NS1 junction),
ChimeriVax–DEN399 (containing a NarI site at the E/NS1 junction), and ChimeriVax–DEN2 control at m.o.i. 0.01. (C) Growth kinetics of ChimeriVax–
DEN400 compared to ChimeriVax–DEN499 uncloned, large- and small-plaque phenotypes.
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(7.2 log) that was 1 log higher than the previous construct
(6.3 log, ChimeriVax–DEN399), but somewhat lower than
the ChimeriVax–DEN2 virus. It appears that the reversion
of the intentional mutation for insertion of a NarI site at
the E/NS1 junction (the Q to G mutation at the penulti-
mate E492 residue) to wt sequence (PvuII virus) might
have slightly improved the growth characteristics of the
chimera compared to a NarI virus). The ChimeriVax–
DEN300–NarI virus was reconstructed in exactly the
same way as the PvuII virus (Materials and Methods),
except that the NarI site was left intact. In an additional
experiment to determine whether peak titers are affected
by m.o.i., Vero cells were infected with the P5 virus at
different m.o.i.s (0.01, 0.1, and 1.0). Daily samples were
collected and titrated by plaque assay. Similar curves
were observed for all m.o.i.s with titers peaking at 7.7–7.9
log10 PFU/ml on Day 3 postinfection (data not shown),
indicating that viral titers were unaffected by 10- to 100-
fold differences in m.o.i.
The growth kinetics of the reconstructed ChimeriVax–
DEN400 (uncloned Vero P3) was compared to Chi-
meriVax–DEN499 (uncloned Vero P3) as well as to large-
and small-plaque variants (cloned Vero P8) of Chi-
meriVax–DEN499 at m.o.i. 0.01 (Fig. 1C). Both uncloned
viruses peaked on Day 4 postinfection (titer 7.5 log10
PFU/ml), whereas the DEN2 control and DEN499 large-
plaque chimeras reached peak titers 1 day earlier (8
and 7.3 log10 PFU/ml, respectively). The small-plaque
phenotype (see Table 1 for mutation) grew to a lower titer
and peaked on Day 4 (titer 6.7 log10 PFU/ml).
Mouse neurovirulence
We previously determined that neither chimeric vi-
ruses nor their parent wt viruses were lethal for 3- to
4-week-old outbred ICR mice inoculated by the intrace-
rebral (ic) route (Guirakhoo et al., 2001). Therefore, to
measure the 50% lethal dose (LD50) of chimeric viruses,
it was necessary to inoculate younger mice within an
age range (4–9 days old) selected to reveal residual
neurovirulence of these viruses. In contrast to Chi-
meriVax–DEN2, which was neurovirulent for 9-day-old
mice with an icLD50 of 3.3 log10 PFU/ml (Guirakhoo et al.,
2001), none of the other chimeras (ChimeriVax–DEN1,
–DEN3, and –DEN4) or their parent strains caused sig-
nificant mortality in 8-day-old mice at doses of up to 5 log
(Table 2). In contrast, yellow fever 17D virus (YF-VAX,
Aventis Pasteur, Swiftwater, PA), representing the back-
bone virus into which DEN prME sequences are in-
serted, is highly neurovirulent, with an icLD50 of 0.56 log10
PFU, 4000-fold lower than that of the DEN1, DEN3, and
DEN4 chimeras.
Monkey studies
The objectives of these studies were to (1) determine
whether reconstruction of chimeric viruses to correct
mutations had changed the safety (viremia) and immu-
nogenicity profiles of the vaccine candidate; (2) evaluate
whether the dominance of chimeric DEN2 [higher immu-
nogenicity than other chimeras when used at equal con-
centration (Guirakhoo et al., 2001)] could be modified by
TABLE 2
Neurovirulence of Chimeric Viruses in 8-day-old ICR Mice
Virus
(passage history)
Titer
(log10 PFU/ml)
Dose
(log10 PFU)
a
Mortality
(%)
AST
(days)
icLD50
(log10 PFU)
ChimeriVax–DEN199 (Vero P4) 7.7 5.0 0/10 (0) 19 5.0
4.0 0/10 (0)
3.0 2/10 (20)
2.0 0/9 (0)
ChimeriVax–DEN3 (Vero P5) 6.5 3.3 0/10 (0) 3.3
2.3 0/10 (0)
1.3 0/10 (0)
ChimeriVax–DEN4 (Vero P5) 7.3 4.3 0/10 (0) 19 4.3
3.3 0/10 (0)
2.3 1/9 (11)
DEN1PUO-359 (C6/36 P3) 6.8 4.9 0/10 (0) 4.9
3.9 0/10 (0)
DEN3PaH881/88 (AP61 P1, C6/36 P1) 7.0 4.3 0/10 (0) 4.3
3.3 0/10 (0)
DEN41228 (Mosquito P2, C6/36 P3) 6.6 4.0 2/10 (20) 12 4.0
3.0 0/10 (0)
YF-VAX (Unpassaged) 5.3b 1.8 8/8 (100) 9.1 0.56
0.8 8/10 (80) 10.5
0.2 1/10 (10) 11
a Determined by back-titration of inocula in Vero cells (chimeric viruses) or in C6/36 cells (wild-type DEN viruses).
b According to the manufacturer’s package insert.
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reducing the dose from 5 to 3 log; and (3) determine
whether antibodies produced in monkeys upon immuni-
zation with one or two doses of a chimeric tetravalent
formulation can neutralize wt dengue viruses isolated
from different geographical locations.
Because the reconstructed DEN1 (ChimeriVax–DEN100)
chimera was not available by the time these monkey ex-
periments had started, this chimera could not be evalu-
ated along with other reconstructed viruses. Therefore the
ChimeriVax–DEN199 was used instead.
Safety and immunogenicity of reconstructed chimeras
Twenty-two of 26 animals inoculated with chimeric
DEN viruses or YF 17D (YF-VAX) control virus became
viremic (exceptions included 1 animal each from Groups
1 and 3, and 2 Group 5 animals) (Table 3). The group
mean peak viremia ranged from 1.8 to 2.7 log10 PFU/ml.
The group mean duration of viremia ranged from 3.7 to
6.3 days. The reconstructed ChimeriVax–DEN300 and
–DEN400 viruses did not significantly differ from their
previous constructs (ChimeriVax–DEN399, and –DEN499
large-plaque variant) in terms of the magnitude and du-
ration of viremia (P  0.2 and 0.7 for the DEN4 and
DEN3 chimeras, respectively; paired t tests). However,
when three DEN4 chimeras (reconstructed, large-
plaque, and small-plaque variants) were compared, the
small-plaque variant induced viremia with a lower mag-
nitude (P  0.001, ANOVA) than other DEN4 viruses;
these data were consistent with the lower in vitro growth
of the small-plaque virus (see Table 1 for mutation and
Fig. 1 for growth curve data). The magnitude and dura-
tion of viremia for all ChimeriVax–DEN viruses (exclud-
ing the small-plaque variant of DEN4 chimera) were
similar to those of YF-17D control virus (P  0.17 and
0.35 for magnitude and duration of viremia, respectively;
ANOVA).
All monkeys seroconverted after one dose of monova-
lent vaccines (as measured by a rise in neutralizing
antibody titer to homologous virus on Day 31). The geo-
metric mean titers (GMT) ranged from 640 to 2560 (Table
4). When responses were compared across groups, in-
cluding the YF 17D control, the large-plaque variant of
ChimeriVax–DEN4 appeared to be the most immuno-
genic virus (P  0.027, ANOVA), followed by YF 17D.
TABLE 3
Viremia in Rhesus Monkeys Immunized sc with ChimeriVax–DEN Monovalent Vaccine Candidates or YF-VAX
Monkey Group
Virus
(dose, log10 PFU)
a
Viremia (log10 PFU/ml) by day post immunization
Peak
titerb
Duration
(days)1 2 3 4 5 6 7 8 9 10 11 12
R14237M 1 ChimeriVax–DEN199 (5.2) 1.0 1.4 0
c 2.1 1.7 0 0 0 0 0 0 0 2.0 3.7
R14256F 1.0 2.1 0 0 0 0 0 0 0 0 0
R14243M 1.4 1.4 0.7 1.9 1.4 0 0 0 0 0 0 0
R14266F 0 0 0 0 0 0 0 0 0 0 0 0
R14206M 2 ChimeriVax–DEN399 (4.4) 0 0 2.3 0 1.7 1.0 0 0 0 0 0 0 1.8 3.7
R14282F 0.7 1.4 1.4 1.0 0 0 1.4 1.4 2.1 0 0 0
R14233M 0 0 0 0 0 1.0 1.0 1.4 0 0.7 0 0
R14284F 0 0 1.4 0 0 0 0 0 0 0 0 0
R14208M 3 ChimeriVax–DEN300 (3.9) 0 0 0 0 0 0 0 0 0 0 0 0 2.1 6.3
R14287F 0 0 1.4 1.0 0.7 1.9 0 0 0 1.3 1.4 0
R14235M 0 0 2.1 1.7 1.9 1.0 1.0 1.4 1.9 2.1 2.5 1.7
R14277F 0 0 0 0 0 1.5 1.0 1.9 0 0 0 0
R14240M 4 ChimeriVax–DEN499,
large plaque (5.0)
0 0 0 0 1.0 0 0 0 2.5 2.6 2.6 2.2 2.4 7
R14257F 1.0 1.3 0.7 0.7 1.7 1.4 1.4 1.9 2.1 2.0 0 0
R14201M 0 0.7 1.0 0 2.4 2.2 0 2.3 2.2 0 0 0
R14252F 5 ChimeriVax–DEN499,
small plaque (4.3)
0 0 0 0 0 0 0 0 0 0 0 0 1.9 7
R14238M 0 0 1.0 0 1.0 1.9 1.0 1.7 1.7 1.4 0 0
R14272F 0 0 0 0 0 0 0 0 0 0 0 0
R14241M 6 ChimeriVax–DEN400 (4.8) 1.7 2.6 2.4 2.9 2.9 2.4 0 0 0 0 0 0 2.7 5.7
R14253F 0 2.1 2.8 2.8 2.5 0 0 0 0 0 0 0
R14242M 2.1 2.8 2.9 2.5 0 0 0 0 0 0 0 0
R14273F 0 1.7 2.2 2.0 1.4 1.7 1.0 1.9 1.0 1.4 0 0
R14234M 7 YF-VAX (5.5) 1.0 1.4 2.0 2.3 0 0 0 0 0 0 0 0 2.3 3.7
R14281F 1.3 1.7 1.4 2.2 0 0 0 0 0 0 0 0
R14214M 1.4 1.3 1.4 1.7 0 0 0 0 0 0 0 0
R14276F 0 2.5 3.0 2.8 0 0 0 0 0 0 0 0
a Determined by back-titration of inocula.
b PFU/ml.
c 0.7 log10 PFU/ml.
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However, when neutralizing antibodies were compared
between reconstructed viruses and their predecessors,
the differences were not statistically significant (P 
0.16 and 0.075 for chimeric DEN3 and DEN4 viruses,
respectively; t tests).
Dose adjustment of DEN2 chimera in the tetravalent
formulation
All animals inoculated with the tetravalent formulation
(containing a nominal dose of 5 log each of DEN1, DEN3,
and DEN4 and 3 log of DEN2 virus) became viremic
(Table 5). The group mean peak viremia in monkeys
immunized with tetravalent chimeras (2.8 log10 PFU/ml)
was significantly lower than that of the wt tetravalent
formulation (4.3 log10 PFU/ml) (P  0.002, t test). The
group mean duration of viremia was also lower in these
monkeys, but the difference was not statistically signifi-
cant (P  0.13, t test).
To determine whether the dose adjustment for chi-
meric DEN2 (nominal 3 log) had resulted in a lower level
of viremia and/or a delay of the onset of viremia, we
tested daily sera (obtained from Day 1 to Day 12 postim-
munization) for the presence of each DEN serotype by an
immunofocus assay. The spectrum of serotypes present
in monkey sera immunized with chimeric tetravalent vi-
ruses differed with inocula, whereas 3 of the 4 monkeys
immunized with wt parent viruses were viremic with all
four DEN serotypes [DEN4 virus was not detected in one
monkey (14280F) (Table 6A)]. ChimeriVax–DEN1, –DEN2,
and –DEN3 viruses were detected in 2/6, 1/6, and 0/6
monkeys of Group 9, respectively. The most frequently
detected chimeric virus was ChimeriVax–DEN4, which
was present for several days in all 6 monkeys (Table 6B).
The magnitude and duration of viremia in the ChimeriVax
tetravalent group were significantly lower than in the wt
tetravalent group (P  0.0001, ANOVA). Among wt vi-
ruses, DEN1 and DEN2 induced a higher magnitude and
longer duration of viremia than DEN3 and DEN4 viruses
(P  0.008, ANOVA for both magnitude and duration of
viremia). However, among chimeric viruses, ChimeriVax–
DEN400 induced a significantly higher magnitude (P 
0.0004, ANOVA) and duration (P  0.0001, ANOVA) of
viremia than the other three chimeras. The onset of
ChimeriVax–DEN2 viremia appeared to be delayed com-
pared to other chimeras, since no virus could be de-
tected in monkey R14207M (the only monkey positive for
DEN2 chimera) until Day 7 (Table 6B).
All monkeys immunized with one dose of the tetrava-
lent formulation (wt or chimeric dengue) developed neu-
tralizing antibodies against all four serotypes. The GMT
ranged from 254 (Group 9 sera against chimeric DEN1)
to 2153 (Group 8 against wt DEN2) (Table 7). The neu-
tralizing antibody titers were significantly higher in Group
8 than in Group 9 (P  0.025, ANOVA). The highest
response in Group 8 animals was directed against DEN2
virus; however, this was not significant (P  0.57,
ANOVA). In contrast, the highest response in Group 9
animals was directed against the DEN4 chimera, which
was highly significant (P  0.009, ANOVA).
Neutralizing antibody responses to homologous
(ChimeriVax–DEN) and heterologous (wt DEN
isolates) viruses after one or two doses
Animals in Group 9 received a second dose (the same
formulation as the first dose) 2 months after the first
dose. No viremia was detected after the second dose
(level of detection was 5 PFU/ml of serum) (data not
shown). The neutralizing antibody titers were measured
against homologous (chimeric DEN) or heterologous [wt
DEN (see Materials and Methods)] viruses using sera
TABLE 4
Neutralizing Antibody Titers (Day 30)a against Homologous Viruses
in Monkeys Immunized with One Dose of Monovalent Viruses
(Groups 1 to 6) or YF-VAX (Group 7)
Monkey Groupa Titer
R14237M 1 1280
R14256F 1280
R14243M 640
R14266F 1280
GMT 1076
R14206M 2 640
R14282F 1280
R14233M 320
R14284F 640
GMT 640
R14208M 3 1280
R14287F 2560
R14235M 640
R14277F 1280
GMT 1280
R14240M 4 2560
R14257F 5120
R14201M 1280
GMT 2560
R14252F 5 1280
R14238M 640
R14272F 640
GMT 806
R14241M 6 320
R14253F 1280
R14242M 640
R14273F 1280
GMT 761
R14234M 7 1280
R14281F 1280
R14214M 2560
R14276F 2560
GMT 1810
a As shown in Table 3.
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obtained pre (Day 1) and post (Day 31) booster immuni-
zations. All six animals developed neutralizing titers
against all serotypes tested after a single dose. The
response was generally higher against homologous vi-
ruses (chimeric DEN) than heterologous viruses. The
highest response was directed against ChimeriVax–
DEN4 virus (GMT  3225). Responses against wt DEN
isolates varied from 80 (GMT against DEN1 from Jakarta
and DEN3 1325 from Sri Lanka) to 1613 (GMT against
DEN4 P75-215 from Malaysia). After the booster dose, all
titers increased (P  0.053, t test, when titers against all
viruses were compared before and after the booster
dose). However, when GMT (before and after booster
immunization) were compared for individual virus iso-
lates, only increases against DEN2 PR 159 from Puerto
Rico (P  0.05, t test), ChimeriVax–DEN4 (P  0.01, t
test), and DEN4 1228 from Indonesia (P  0.057, t test)
were statistically significant (Table 8).
DISCUSSION
ChimeriVax–DEN1, –DEN3, and –DEN4 viruses were
reconstructed to correct mutations that were introduced
by primer errors or inadvertently during constructions of
the parent plasmids. Following reconstructions, virus
stocks were prepared by transfection of Vero cells (P1)
with in vitro RNA transcripts followed by one additional
round of amplification (P2). The reconstructed viruses
were sequenced before inoculation into monkeys and
generally shown to be free of mutations, with some
exceptions; ChimeriVax–DEN3 contained a single nucle-
otide heterogeneity (A/C nucleotides encoding E/D
amino acid heterogeneity at residue 18 of the prM pro-
tein) at Vero P5. Additional experiments revealed that this
heterogeneity first appeared at P3. Because the mutation
is located in an N-terminal part of the prM protein that is
cleaved out during virus assembly and is not present in
the envelope of mature virions, it is considered to be
insignificant. However, it might be present on immature
viral particles containing uncleaved prM proteins, the
effect of which on virus infectivity is unknown at this time.
The reconstructed DEN1 chimera also retained one mu-
tation (A to G nucleotide change resulting in an H to R
amino acid substitution at residue M39). The reconstruc-
tion of this virus [which had been hampered by instability
of its plasmids in Escherichia coli hosts and requirement
of additional alternative PCR amplifications (Guirakhoo
et al., 2001)] was not completed on time. Therefore, this
virus was not evaluated in monkeys. The instability of
DEN1 genes was overcome by cloning in a 3-plasmid
system of low copy numbers. The M39 mutation (deter-
mined later to be present in plasmids) was corrected,
and a seed virus was produced and evaluated in mice
and monkeys (to be reported elsewhere). It is likely that
the present mutations, arising at an early stage of viral
passages, had been produced from infidelity of the SP6
polymerase enzyme used for in vitro RNA transcription
(K. Pugachev, unpublished data). For this reason, our
current strategy for cGMP production of these chimeras
incorporates three rounds of plaque purification imme-
diately after transfection. Indeed, plaque-purified seeds
of all four chimeric viruses at P7 revealed no uninten-
tional mutations across the entire genome (data not
shown). Moreover, plaque-purified chimeras accumu-
lated fewer mutations than their uncloned counterparts
when continuously passaged in Vero cells at an m.o.i. of
0.001 up to 20 passages posttransfection (data not
TABLE 5
Viremia in Rhesus Monkeys Immunized sc with wt or ChimeriVax–DEN Tetravalent Vaccine Candidates
Monkey Group
Virus
(dose, log10 PFU)
a
Viremia (log10 PFU/ml) by day postimmunization
Peak
titerb
Duration
(days)1 2 3 4 5 6 7 8 9 10 11 12
R14226M 8 wt DENc
(D1  4.4,
D2  4.0,
D3  5.4,
D4  4.8)
1.7 2.7 2.3 2.2 2.3 3.5 3.1 3.5 3.4 1.7 1.7 1.7 4.3 8.5
R14280F 1.7 2.2 2.6 3.7 4.8 5.0 4.2 3.3 1.7 1.7 1.7 1.7
R14230M 1.7 1.7 3.3 3.4 3.2 3.9 4.3 4.7 3.2 2.7 1.7 1.7
R14271F 1.7 2.7 3.0 3.1 3.6 4.0 4.1 3.4 2.6 2.3 1.7 1.7
R14207M 9 ChimeriVax–DEN
(YF/D1  4.5,
YF/D2  3.0,
YF/D3  3.6,
YF/D4  4.4)
1.7 3.2 2.5 2.3 1.7 2.4 2.1 2.3 2.5 2.7 1.6 1.4 2.8 6d
R14286F 2.6 3.2 2.7 1.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
R14210M 1.3 2.2 2.0 1.7 2.1 1.4 1.0 2.0 1.7 1.0 1.0 1.0
R14265F 1.6 1.7 2.1 2.2 2.6 1.0 1.0 1.0 1.0 1.0 1.0 1.0
R14244M 1.0 1.9 2.6 2.6 3.1 2.8 2.2 1.7 1.0 1.0 1.0 1.0
R14269F 2.3 2.4 2.2 1.9 2.3 1.0 1.0 1.0 1.0 1.0 1.0 1.0
a Determined by back-titration of inocula.
b PFU/ml.
c D1; PUO-359, C6/36 P2. D2; S16803, PGMK P4, C6/36 P3., D3; PaH881, AP61 P1, C6/36 P2., D4; 1228, mosquito P2, C6/36 P2 (see also Table 9).
d Days with viremia below 1.7 PFU/ml are not calculated to be comparable to the wild-type Group 8.
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shown). It appears that reconstruction of ChimeriVax–
DEN1 and –DEN4 to correct mutations did not diminish
their replication efficiency in Vero cells, and the recon-
structed chimeric DEN3 virus grew to an even higher titer
(1 log10 PFU/ml) than an earlier construct containing
mutations.
Most flaviviruses are neurovirulent for young mice,
and many show decreasing virulence for older animals
(Monath, 1986). Unadapted dengue viruses are among
the least neurovirulent flaviviruses. Although neuroviru-
lence for mice and attenuation for monkeys inoculated
by the peripheral route do not correlate for dengue vi-
TABLE 6
Serotype-Specific Viremia in Monkeys Immunized with Tetravalent wt Dengue (A) or ChimeriVax–DEN (B) Viruses
A. Monkey
Serotype
detected
Viremia (log10 PFU/ml) by day postimmunization
Peak
titer
Duration
(days)1 2 3 4 5 6 7 8 9 10 11
R14226M D1 0a 1.7 2.3 2.2 2.3 3.2 3.0 3.1 3.0 0 0 3.2 8
D2 0 0 0 0 0 2.7 2.7 2.7 3.2 1.7 0 3.2 5
D3 0 2.7 0 2.0 0 3.0 2.6 2.7 0 0 0 3.0 5
D4 0 0 0 0 0 0 0 0 0 0 0 0 0
R14280F D1 0 0 2.0 2.0 2.7 3.8 3.5 3.3 0 0 0 3.8 7
D2 0 0 2.0 3.7 4.8 5.0 4.2 0 0 0 0 5.0 5
D3 0 2.0 2.3 2.0 2.3 2.5 2.7 0 0 0 0 2.7 6
D4 0 1.7 1.7 2.7 3.0 2.7 0 0 0 0 0 2.7 5
R14230M D1 0 0 2.7 2.6 2.7 3.5 3.5 3.3 0 0 0 3.5 6
D2 0 0 2.4 3.2 3.0 3.6 4.2 4.7 3.2 2.7 0 4.7 8
D3 0 0 3.0 2.8 1.7 2.2 1.7 0 0 0 0 3.0 5
D4 0 0 2.5 1.7 1.7 1.7 0 0 0 0 0 2.5 4
R14271F D1 0 0 0 2.3 2.5 3.0 3.2 2.6 2.5 2.2 0 3.2 7
D2 0 0 1.7 2.7 3.6 3.9 4.6 3.3 2.0 1.7 0 4.6 8
D3 0 2.7 3.0 0 0 2.7 0 0 1.7 0 0 3.0 4
D4 0 0 0 0 0 2.0 2.7 0 0 0 0 2.7 2
a 1.7 log10 PFU/ml.
B. Monkey
Serotype
detected
Viremia (log10 PFU/ml) by day postimmunization
Peak
titer
Durationa
(days)1 2 3 4 5 6 7 8 9 10 11
R14207M D1 0b 2.4 0 1.4 0 0 0 0 0 0 0 2.4 1
D2 0 0 0 0 0 0 1.4 1.4 1.7 2.7 0 2.7 2
D3 0 0 0 0 0 0 0 0 0 0 0 0 0
D4 0 2.0 1.7 1.4 1.4 1.4 1.7 1.9 2.7 1.4 0 2.7 5
R14286F D1 0 2.0 0 0 0 0 0 0 0 0 0 2.0 1
D2 0 0 0 0 0 0 0 0 0 0 0 0 0
D3 0 0 0 0 0 0 0 0 0 0 0 0 0
D4 1.7 2.7 2.5 2.1 0 0 0 0 0 0 0 2.7 4
R14210M D1 0 0 0 0 0 0 0 0 0 0 0 0 0
D2 0 0 0 0 0 0 0 0 0 0 0 0 0
D3 0 0 0 0 0 0 0 0 0 0 0 0 0
D4 0 1.7 1.4 1.4 0 1.7 0 1.7 0 1.4 0 1.7 3
R14265F D1 0 0 0 0 0 0 0 0 0 0 0 0 0
D2 0 0 0 0 0 0 0 0 0 0 0 0 0
D3 0 0 0 0 0 0 0 0 0 0 0 0 0
D4 1.7 2.3 1.9 1.4 2.0 0 0 0 0 0 0 2.3 4
R14244M D1 0 0 0 0 0 0 0 0 0 0 0 0 0
D2 0 0 0 0 0 0 0 0 0 0 0 0 0
D3 0 0 0 0 0 0 0 0 0 0 0 0 0
D4 1.7 2.3 1.9 1.4 2.0 0 0 0 0 0 0 2.3 4
R14269F D1 0 0 0 0 0 0 0 0 0 0 0 0 0
D2 0 0 0 0 0 0 0 0 0 0 0 0 0
D3 0 0 0 0 0 0 0 0 0 0 0 0 0
D4 0 1.9 1.9 0 2.4 2.2 2.2 1.9 0 0 0 2.4 6
a Days with peak titers lower than 1.7 log are not considered comparable to Table 6A.
b 1.4 log10 PFU/ml.
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ruses (for example, wt DEN viruses are attenuated for
mice, but induce high viremia in monkeys), it was impor-
tant to demonstrate that reconstruction of chimeric vi-
ruses using the YF 17D backbone had not increased the
neurovirulence of chimeras beyond that of YF-VAX, which
is associated with rare postvaccinial adverse effects
(Monath et al., 1999; Galler et al., 2001). The seed virus of
ChimeriVax–DEN2 used for cGMP production of a clini-
cal vaccine lot had an icLD50 of 2.2 log10 PFU (in 8.4-day-
old mice) and was significantly less neurovirulent than
YF-VAX (icLD50 0.34 log10 PFU) (data not shown). In con-
trast, ChimeriVax–DEN1, –DEN3, and –DEN4 did not
cause significant mortality in 8.3-day-old mice, even
when used undiluted (dose5 log10 PFU). It appears that
these viruses are less neurovirulent than other chimeras
[e.g., chimeric DEN2 or chimeric JE (Guirakhoo et al.,
1999, 2000)]. Since all four DEN wt viruses used for
construction of these chimeras were attenuated for suck-
ling mice [Gualano et al. (1998); Guirakhoo et al. (2000);
and Table 2], and only chimeric DEN2 exhibited some
neurovirulence in younger suckling mice (9 days old), it
is likely that neurovirulence of chimeric DEN2 is deter-
mined by both DEN and YF genes. We have already
established a correlation between suckling mouse and
monkey neurovirulence for the ChimeriVax–JE vaccine
using a single site revertant virus (Monath et al., 2002a)
and are currently assessing the neurovirulence of a chi-
meric DEN2 vaccine produced under cGMP in monkeys
according to the protocol proscribed by the WHO regu-
lation for safety testing of YF vaccines (WHO, 1998).
Current data suggest that the suckling mouse is an
appropriate host to predict virulence profiles of Chi-
meriVax viruses in monkeys (Monath et al., 2002a).
Administration of various chimeras by subcutaneous
(sc) injection of doses up to 5.0 log10 PFU in rhesus
monkeys was well tolerated, and there were no vaccine-
related changes in clinical signs or body weights. Be-
cause increased severity of dengue disease in humans
correlates with high viremia (Vaughn et al., 2000), we
compared the level of viremia induced by wt viruses to
those induced by chimeric viruses. Viremia induced by
all monovalent vaccines, including YF-VAX, was low and
generally statistically similar (P  0.17 for peak viremia
and P  0.35 for duration, ANOVA), with the exception of
the YF/DEN499 small-plaque virus. The magnitude of vire-
mia (but not its duration) induced by this plaque variant
was significantly lower than its large-plaque variant (P 
0.056, t test) or YF-VAX (P  0.043, t test). The virus
differed from the large-plaque variant at E277, E366, and
E437 and from its uncloned parent virus at the E4 and
E437 residues (Table 1). Interestingly, a ChimeriVax–JE
virus containing a single amino acid substitution (M to K)
at position E279 also induced small plaques in Vero
cells, as well as a lower (than the virus without mutation)
viremia in monkeys (Monath et al., 2002a). Mice and
monkeys seem to be appropriate models for testing the
safety and efficacy of ChimeriVax-based flavivirus vac-
cines, and a good correlation has been established be-
tween mice, monkeys, and humans in terms of safety
and immunogenicity of the ChimeriVax–JE vaccine
(Guirakhoo et al., 1999; Monath et al., 1999, 2000, 2002b).
The safety of the chimeric tetravalent vaccine was
measured by comparing the magnitude of viremia of
Group 9 monkeys to that of Group 8 (tetravalent wt
formulation) using t tests. The magnitude of viremia in
the tetravalent chimera group was significantly lower
than that in the wt group (P  0.002) and was consistent
with our previous observations, where chimeric and wt
parent viruses were compared as monovalent vaccines
(Guirakhoo et al., 2001). Relatively high titers of all wt
DEN serotypes were detected in monkeys immunized
with the tetravalent wt formulation, with the exception of
one animal in which wt DEN4 could not be detected
(monkey R14226 in Table 6A). In contrast, chimeric vi-
ruses were detected less frequently and at lower titers
when used as a tetravalent mixture. This is not surpris-
ing, considering that most of these viruses induce low
levels of viremia (0.7 to 2.0 log) when individually ad-
ministered to monkeys. In monkeys immunized with the
tetravalent DEN vaccine, chimeric DEN4 virus was the
only chimera that was detected in all six animals (Table
6B). This virus (as well as its large-plaque variant) in-
duced significantly higher levels of viremia (2.4–2.7 log10
PFU/ml) than other chimeras (P  0.04) when inocu-
lated as a monovalent vaccine (Table 3). In a previous
study, where six monkeys were immunized with a tet-
TABLE 7
Neutralizing Antibody Titers (Day 30)a against Homologous Viruses
in Monkeys Immunized with One Dose of Tetravalent-wt (Group 8)
or –Chimeric (Group 9) Viruses
Monkey Group
50% Neutralizing titers (Day 30)
against homologous virusesb
DEN1 DEN2 DEN3 DEN4
R14226M 8 320 320 640 160
R14280F 1280 2560 640 320
R14230M 2560 5120 2560 5120
R14271F 1280 5120 5120 1280
GMT 1076 2153 1522 761
R14207M 9 2560 10240 320 1280
R14286F 640 160 160 1280
R14210M 80 80 80 640
R14265F 320 320 320 2560
R14244M 160 640 320 2560
R14269F 320 160 640 1280
GMT 359 403 254 1437
a Titers of all sera taken immediately before vaccination were 10
and are not shown in this table.
b For neutralization of Group 8 sera wt parent DEN1–4 and for
neutralization of Group 9 sera chimeric DEN 1–4 viruses were used.
Boldface numbers are geometric mean titers of 50% neutralization
titers.
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ravalent formulation consisting of equivalent doses of
each chimera, DEN2 and DEN4 chimeras were detected
in the sera of five monkeys and one monkey, respectively.
It appears that adjusting the tetravalent formulation to
include a lower dose of DEN2 virus has reduced its
replication in favor of chimeric DEN4 virus. A similar
dominant effect of the DEN2 virus was observed in mon-
keys inoculated with5 log of a bivalent dengue vaccine
(consisting of C, prME genes of DEN1, or prME genes of
DEN2 virus inserted into the backbone of a DEN4 virus).
While the DEN2/DEN4 chimera was isolated from seven
of eight monkeys, no DEN1/DEN4 chimera could be
detected in any of these animals (Bray et al., 1996).
Similar to the DEN1/DEN4 chimera, ChimeriVax–DEN3
could not be detected in any of the monkeys immunized
with the tetravalent vaccine (despite the fact that seven
of eight monkeys inoculated with this virus as a mono-
valent vaccine became viremic with a mean peak titer of
2 log10 PFU/ml).
As mentioned above, chimeric DEN3 contained a nu-
cleotide heterogeneity (A/C at position 54, Table 1). To
determine which virus subpopulation had replicated in
monkeys, 17 plaques, representing both early and late
viremia, were isolated from sera (monkeys R14287,
R14235, and R14277; see Table 3) and sequenced. Fif-
teen viruses contained the mutant C nt and two con-
tained the wt A nt. The two isolates with wt A nt were
from late viremia (monkey R14287, Day 11; and monkey
R14235, Day 12). Thus, both mutant and nonmutant vari-
ants cocirculated in animals with evidence that the mu-
tant virus was being preferentially selected.
Despite the lack of detectable viremia in some mon-
keys, all immunizations induced high levels of neutraliz-
ing antibody titers, indicating sufficient replication of
these viruses after a single sc inoculation. There were no
statistically significant differences in levels of neutraliz-
ing antibodies between reconstructed and original chi-
meras, indicating that the mutations found in the original
chimeras had not affected their immunogenicities in
monkeys. This finding provides some assurances that
minor genetic variations induced during scale-up manu-
facturing or in vivo replication will not affect vaccine
performance. In addition, there were no statistical differ-
ences in levels of neutralizing antibodies between chi-
meric DEN4 small- and large-plaque variants (P 
0.14). However, when antibody responses were com-
pared across all groups including that given YF-VAX, the
highest antibody response was observed in monkeys
that received the ChimeriVax–DEN499 large-plaque virus
(P  0.03) (Group 4 in Table 4). It is possible that
selection of this variant in monkey-derived cells (Vero)
and acquisition of mutations have improved its immuno-
genicity for monkeys.
Sera obtained from all monkeys after application of a
TABLE 8
Neutralizing Antibody Titers of Group 9 Monkeys against Homologous (Chimeric DEN) and
Heterologous (wt DEN Isolates) Viruses before and after the Second Dose
Virus
50% neutralizing antibody titers against indicated dengue viruses by monkey
GMT
P
valuea
R14207 R14286 R14210 R14265 R14244 R14269
Preb Postc Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post
YF/DEN1 1280 5120 1280 5120 320 640 2560 2560 160 640 320 1280 640 1810 0.12
PUO359 160 320 160 320 160 160 320 640 80 160 40 80 127 226 0.19
BrazilBEH455823 640 640 320 640 320 320 1280 2560 320 320 160 320 403 570 0.47
Jakarta85-464 160 320 320 640 160 160 640 1280 80 320 80 320 80 403 0.19
YF/DEN2 5120 5120 1280 1280 640 1280 1280 1280 2560 2560 640 1280 1437 1613 0.80
PUO218 1280 640 320 640 320 160 640 640 640 1280 320 1280 508 640 0.44
JAH 640 640 320 1280 160 320 640 640 320 640 320 320 359 570 0.17
PR159 640 1280 320 1280 320 320 640 1280 160 640 160 320 320 718 0.050
YF/DEN3 1280 2560 640 640 320 640 1280 1280 640 1280 320 640 640 1016 0.26
PaH88/81 640 1280 320 320 320 320 640 640 320 320 320 1280 403 570 0.22
1301 320 640 80 40 160 80 160 160 40 40 160 320 127 127 0.57
1325 160 320 40 80 80 160 80 160 40 40 160 160 80 127 0.21
YF/DEN4 2560 5120 2560 5120 2560 5120 5120 5120 5120 5120 2560 5120 3225 5120 0.01
1228 640 640 320 1280 320 320 640 1280 320 640 320 640 403 718 0.057
BC26-97 1280 1280 5120 1280 1280 1280 1280 2560 1280 1280 1280 1280 1613 1437 0.54
P75-215 320 640 160 640 40 160 80 160 80 80 40 40 90 180 0.20
a The 50% neutralization titers against individual dengue viruses (Table 9) were compared by t tests using sera obtained pre and post booster
immunization. Boldface numbers in the P value column represent statistically significant increases in levels of antibodies between pre- and
postimmunization sera measured against individual DEN strains.
b Obtained 61 days after the first dose and prior to the second dose (Day 63).
c Obtained 31 days after the second dose.
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single dose of the tetravalent chimeras (Group 9) neu-
tralized wt dengue viruses collected from various geo-
graphical regions, suggesting the effectiveness of this
tetravalent vaccine against a wide range of wt DEN
strains (Table 8). These wt viruses had been selected
from a library of dengue viruses (consisting of epidemic/
endemic or sylvatic strains) based on their genotypic
(American or Asian) differences (Table 9). Although ap-
plication of a second dose of the tetravalent formulation
resulted in two- to fourfold increases in titers of neutral-
izing antibodies against all four dengue serotypes (Table
8), the interval between the priming dose and boosting
dose was, however, short (60 days), and more significant
effects might be expected when booster doses are given
at longer intervals.
In sum, it appears that the reconstructed viruses
tested here are safe (induction of low viremia) and im-
munogenic in monkeys after one dose (100% serocon-
version). Immunization with tetravalent chimeras pro-
vided high levels of neutralizing antibodies against wt
dengue viruses representing different geographic areas,
and titers were increased by administration of a second
dose. The dominance of the immune response against
YF/DEN2 (Guirakhoo et al., 2001) in the tetravalent for-
mulation could be regulated by application of a lower
dose. However, it appears that the dose of YF/DEN4 (and
possibly other chimeras) needs to be adjusted as well.
These observations indicate that it is necessary to eval-
uate additional tetravalent formulations in monkeys to
find the optimal dose of each serotype to be incorporated
into a formulation for testing in a Phase 1 human trial.
MATERIALS AND METHODS
Reconstruction of ChimeriVax dengue viruses
Amino acid substitutions in the prME regions of the
original ChimeriVax–DEN1, –DEN3, and –DEN4 con-
structs (designated ChimeriVax–DEN199, –DEN399, and
–DEN499) (Guirakhoo et al., 2001) were reverted to wt
residues, and reconstructed viruses (designated Chi-
meriVax–DEN100, –DEN300, and –DEN400) were prepared
by transfection of Vero cells with RNA transcripts as
described previously (Guirakhoo et al., 2001) (see below
for details).
Reconstruction of ChimeriVax–DEN1 and –DEN4 vi-
ruses. Sequencing analysis of plasmids used for con-
struction of these viruses revealed that some mutations
were introduced due to errors in the synthesis of prim-
ers. These primers were resynthesized, new Chi-
meriVax–DEN100 and –DEN400 constructed as described
previously (Guirakhoo et al., 2001) and sequenced
across the prME regions (Table 1). An L to F mutation at
amino acid E56 of ChimeriVax–DEN499 (nt 666) (Table 1)
was corrected by changing nt T to C at adjacent nt 664.
Reconstruction of ChimeriVax–DEN3 virus. To elimi-
nate amino acid substitutions in the envelope region of
ChimeriVax–DEN399, as well as the majority of silent
nucleotide changes including those introduced by using
nonstrain (DEN3 H87 virus) -specific primers or inten-
tionally engineered as restriction sites [e.g., the E492
mutation, Table 1, and Guirakhoo et al. (2001)], new
oligos based on the sequence of the parent wt DEN3
(strain PaH881/88) were synthesized. These oligos were
TABLE 9
Origin and Passage History of wt Dengue Viruses
Dengue
serotype Strain No.
Country of
origin
Origin of
virus
Collection
date Passage history Genotypea
1 PUO-359, TVP-1140 Thailand Human plasma 1980 C6/36 P2 II?
1 BE H 455823 Brazil Human serum 1986 C6/36 P2 II?
1 JKT 85-464 Indonesia Human serum 1985 C6/36 P2 I?
2 PUO-218 Thailand Human plasma 1980 Mosq P1, LLCMK2 P1,
Vero P1, C6/36 P2
IIIa
2 S16803 Thailand Human 1974 PGMKb P4, C6/36 P3 I?
2 JAH Jamaica Human 1982 C6/36 P2 IIIb?
2 PR159 Puerto Rico Human 1969 Mosq P1, C6/36 P2 I
3 PaH881/88 Thailand Human 1988 AP61 P1, C6/36 P1 II
3 1301 Malaysia Human serum 1975 Mosq P2, C6/36 P2 I?
3 1325 Sri Lanca Human serum 1981 Mosq P2, C6/36 P2 III?
4 1228 (TVP-980) Indonesia Human serum 1978 Mosq P2, C6/36 P2 II?
4 BC 26-97 Mexico Human 1996 C6/36 P3 II?
4 P 75-215 Malaysia Mosquito 1975 ?, C6/36 P2 I?
a Genotypes of these viruses have not yet been determined with the exception of PUO-218 (Lewis et al., 1993; Uzcategui et al., 2001) and PR159
(Zin et al., 1995a,b) strains of DEN2 and PaH881/88 strain of DEN3 (Deubel, 1997) viruses. The assumed genotypes (shown with ?) are based on
published information of other strains isolated from similar geographical locations: Chungue et al. (1995) for DEN1 viruses; Lewis et al. (1993),
Rico-Hesse (1998), Singh et al. (1999), and Usuku et al. (2001) for DEN2 viruses; Kobayashi et al. (1999) for DEN3 viruses; and Lanciotti et al. (1997)
for DEN4 viruses.
b Primary green monkey kidney cells.
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used to amplify the DEN3-specific region of 53/Den3/
XhoI plasmid (Fig. 2) in which the mutations [except for
the two silent nucleotide changes at nt 9 (G to A) and 18
(C to A) of the prM gene] were reversed. The corrected
plasmid was designated 53/Den3/EcoRI. The BstBI–
NarI DEN3-specific part of the 5.2/Den3 plasmid (Guirak-
hoo et al., 2001) was also amplified such that the NarI
site was replaced with PvuII, and the PCR product was
cloned in a modified low-copy-number vector, pCL 1921,
resulting in plasmid pCL/D3E/PvuII (Fig. 2). The rein-
serted parts of new plasmids were sequenced across
both strands to ensure the absence of any PCR- or E.
coli-induced mutations. To generate a DNA template for
in vitro transcription, three-fragment ligation was per-
formed as shown in Fig. 2. The BstBI–PvuII fragment of
pCL/D3E/PvuII and the NarI–AatII fragment of plasmid
YFM5.2/DEN2 (containing YF-specific NS genes) were
ligated with the large BstBI–AatII portion of 53/Den3/
EcoRI. Ligation products were linearized with XhoI and
used for in vitro transcription with SP6 RNA polymerase.
ChimeriVax–DEN300 virus was produced following trans-
fection of Vero cells with the RNA transcripts. In contrast
to the ChimeriVax–DEN399 (Guirakhoo et al., 2001) this
new chimera was generated using only cDNA fragments
derived from plasmids (without the PCR amplification
step), thus eliminating the possibility of random PCR-
induced nucleotide changes in the template. In addition,
ligation between the PvuII and NarI blunt ends elimi-
nated the E492 amino acid change at the E/NS1 junction.
Thus, the new virus contained the authentic PaH881/88-
specific signal for NS1.
Cells and viruses
Vero cells used to produce and assay ChimeriVax–
DEN viruses were obtained from Aventis Pasteur (Lyon,
France). They were used between passages 141 and 151
for transfection of chimeric viruses and between pas-
sages 143 and 170 for other assays, such as plaque
assays and neutralization tests. C6/36 cells used to grow
wt DEN viruses were obtained from the American Type
Culture Collection (ATCC, Manassas, VA). Wild-type
DEN1 viruses used were strains PUO-359, Thailand
1980; BE H 455823, Brazil 1986; and 85-464, Indonesia
1985. Wild-type DEN2 viruses used were strains PUO-
218, Thailand 1980; S16803, Thailand 1974; JAH, Jamaica
1982; and PR 159, Puerto Rico 1969. Wild-type DEN3
viruses were strains PaH881/88, Thailand 1988; 1301,
Malaysia 1975; and 1325, Sri Lanka 1981. Wild-type DEN4
viruses used were strains 1228, Indonesia 1978; BC
26-97, Mexico 1996; and P75-215, Malaysia 1975. These
viruses, which were selected from a library of low-pas-
sage wt dengue viruses based on geographic origin and
putative genotypic differences, are all representative of
the human–A. aegypti dengue virus transmission cycle
with the exception of DEN3 P75-215. This virus is con-
sidered to be a “sylvatic” strain because it was isolated
from canopy-dwelling mosquitoes (A. niveus) (Wang et
al., 2000) (Table 9). Chimeric viruses used in these stud-
ies were ChimeriVax–DEN199 (VeroP4), ChimeriVax–
DEN2 (VeroP3), ChimeriVax–DEN399 (VeroP4), Chi-
meriVax–DEN300 (VeroP5), ChimeriVax–DEN499 (three-
times plaque-purified large- and small-plaque variants,
VeroP8), and ChimeriVax–DEN400 (VeroP5) (Table 1).
Commercial YF 17D vaccine (YF-VAX) was purchased
from Aventis Pasteur (Lyon, France) and used unpas-
saged.
Animal studies
All studies were carried out under an Institutional
Animal Care and Use Committee (IACUC) approved pro-
tocol in accordance with the USDA Animal Welfare ACT
(9 CFR Parts 1–3) as described in the Guide for Care and
Use of Laboratory Animals (NIH, 1998).
Neurovirulence of viruses was determined in suckling
mice born on site from pregnant ICR mice (Taconic Farm,
Inc., Germantown, NY). Mice were pooled at 3 days of
age to reduce genetic variations within the assay, ran-
domly redistributed to mothers (10 sucklings/mother),
and inoculated at 8 days of age with 20 l of virus
suspension by the intracerebral route. Animals were
observed for 21 days, and mortality was recorded. Any
animal found in an advanced moribund stage was eu-
thanized according to the IACUC protocol. Mortality ra-
tios by dose, LD50 values, were calculated by the Reed
and Muench (1938) method.
Experiments with monkeys were performed at Sierra
Biomedical Inc. (Sparks, NV). Thirty-six male and female
(18 male/18 female) rhesus monkeys (Macaca mulatta,
Chinese origin), 2.7–6.3 years of age, weighing 2.7 to 5.6
kg, were divided into nine groups (Tables 3 and 5). On
Day 1, each animal received a single dose of monovalent
chimeric DEN (Groups 1 to 6), tetravalent wt (Group 7),
FIG. 2. The three-fragment ligation to generate ChimeriVax–DEN300
virus.
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YF-VAX (Group 8), or tetravalent chimeric DEN (Group 9)
virus. Animals in Group 9 received a booster dose on 63.
The tetravalent formulations (containing chimeric or wt
viruses) consisted of nominal doses of 5 log each of
DEN1, DEN3, and DEN4 viruses and 3 log of DEN2 virus.
The lower dose of DEN2 chimera was used because, in
our previous study in monkeys (Guirakhoo et al., 2001), it
apparently replicated more efficiently than the other chi-
meras, as reflected by higher antibody responses and
viremia. All animals were evaluated twice daily for
changes in clinical signs, including a qualitative assess-
ment of daily food consumption. Body weight was mea-
sured weekly. Blood samples were collected prior to
administration of viruses (on Day 1) and on Days 31 and
61 (as well as on Day 94 for the animals in Group 9) for
determination of DEN-specific neutralizing antibodies.
Additional blood samples were collected predose (Day
1) and on Days 2–13 for determination of viremia. After
the last sample collection, animals were returned to their
colony.
Plaque assays and neutralization tests
Plaque assays for detection of chimeric viruses in sera
or tissue culture supernatants were performed using
Vero (for chimeric viruses) or C6/36 (for wt DEN viruses)
cells as described (Monath et al., 2000; Guirakhoo et al.,
2001). For identification of DEN serotypes in serum sam-
ples of monkeys immunized with tetravalent formulations
(Groups 8 and 9, Tables 5 and 6), we used an immuno-
cytochemical focus-forming assay in Vero (for chimeras)
or C6/36 (for wt DEN) cells. Sera obtained on Days 1–12
postimmunization were diluted 1:10, 1:100, and 1:1000
(for Group 8) and 1:5 (for Group 9). Samples were run in
duplicate, and plaques, representing each of the four
DEN serotypes, were identified by immunostaining with
dengue serotype-specific monoclonal antibodies (Guira-
khoo et al., 2001). Neutralizing antibody titers were mea-
sured on heat-inactivated sera without addition of com-
plement using Vero cells (Guirakhoo et al., 2001). Be-
cause chimeric viruses replicate efficiently in Vero cells
and produce relatively large plaques (1–2 mm in diame-
ter), a standard neutralization assay using a double aga-
rose overlay and neutral red was used for these viruses
(Monath et al., 2000). In contrast, wt dengue viruses
produce extremely small plaques (1 mm in diameter) in
Vero cells, making it difficult to count plaques after the
addition of neutral red. For this reason neutralizing titers
(in sera obtained after immunization with chimeras)
against wt dengue viruses were measured in an im-
munofocus assay using DEN group reactive polyclonal
antibodies (1:2000 dilution of 2H2 hybridoma obtained
from ATCC) followed by anti-mouse IgG conjugated to
horseradish peroxidase (Guirakhoo et al., 2001). Fifty
percent titers were determined as the last dilution of
serum and virus mixture that reduced the number of
plaques by 50% (compared to the virus alone).
Statistical analysis
Differences in responses across multiple groups and
between two groups were analyzed for significance us-
ing ANOVA and t tests, respectively (JMP software ver-
sion 4.0.2).
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